title: Acute T-lymphoblastic leukemia relapsed with the character of myeloid/natural killer cell precursor phenotype: a case report.
abstract: The leukemic lymphoblasts of a patient expressed CD7, CD13, CD33, CD34, HLA-DR and cytoplasmic CD3varepsilon. He was diagnosed with acute lymphoblastic leukemia (ALL), and successfully treated with a conventional chemotherapy for ALL. The disease relapsed three times, and the character of the cells gradually altered, i.e. CD56 expression increased and CD13, CD7 and cCD3 epsilon decreased. The phenotype of the relapsed ALL was, therefore, compatible with myeloid/natural killer cell precursor acute leukemia (M/NK-AL). Some of M/NK-AL may be closely related with T/myeloid-biphenotypic pro-T blasts, and both types of acute leukemia may develop a tendency to express myeloid antigens, and they may belong to the category of immature T lymphoid precursors.
authors.affiliation: First Department of Internal Medicine, Niigata University School of Medicine, Asahimachi-dori 1, Niigata City 951-8510, Japan.
authors.forename: Shigeo
authors.initials: S
authors.lastname: Hashimoto
authors.forename: Ken
authors.initials: K
authors.lastname: Toba
authors.forename: Sadao
authors.initials: S
authors.lastname: Aoki
authors.forename: Junjiro
authors.initials: J
authors.lastname: Tsuchiyama
authors.forename: Nobuhiro
authors.initials: N
authors.lastname: Tsukada
authors.forename: Hidenobu
authors.initials: H
authors.lastname: Takahashi
authors.forename: Masuhiro
authors.initials: M
authors.lastname: Takahashi
authors.forename: Yoshifusa
authors.initials: Y
authors.lastname: Aizawa
mesh_terms: D015703:Antigens, CD / Q000032:analysis*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D019070:Cell Lineage; D003131:Combined Modality Therapy; D003630:Daunorubicin / Q000008:administration & dosage; D018450:Disease Progression; D017809:Fatal Outcome; D015333:Gene Rearrangement, beta-Chain T-Cell Antigen Receptor; D005803:Genes, Immunoglobulin; D006021:Glycophorins / Q000032:analysis; D006684:HLA-DR Antigens / Q000032:analysis; D006801:Humans; D016130:Immunophenotyping; D007694:Killer Cells, Natural / Q000737:chemistry / Q000473:pathology; D007945:Leukemia, Lymphoid / Q000188:drug therapy / Q000473:pathology* / Q000532:radiotherapy; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D022423:Myeloid Cells / Q000737:chemistry / Q000473:pathology; D009363:Neoplasm Proteins / Q000032:analysis*; D014411:Neoplastic Stem Cells / Q000737:chemistry*; D009195:Peroxidase / Q000032:analysis; D011239:Prednisolone / Q000008:administration & dosage; D012008:Recurrence; D012074:Remission Induction; D016176:T-Lymphocyte Subsets / Q000737:chemistry / Q000473:pathology; D014184:Transplantation, Homologous; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D015703:Antigens, CD; D006021:Glycophorins; D006684:HLA-DR Antigens; D009363:Neoplasm Proteins; D014750:Vincristine; D011239:Prednisolone; D009195:Peroxidase; D008727:Methotrexate; D003630:Daunorubicin